New Imaging Technology Could Reduce Benign Breast Biopsies by 25%
For many patients, the recommendation for a breast biopsy is a source of intense anxiety. While a biopsy is currently the only diagnostic procedure that can definitively determine if a suspicious lump or area is cancerous, the vast majority of these procedures do not find cancer. In the United States, between 75% and 80% of breast biopsies are benign. This high rate of non-cancerous results suggests a significant opportunity to improve how doctors triage breast lesions.
A recent clinical trial has introduced a noninvasive imaging technique that could significantly reduce these unnecessary procedures. By combining standard ultrasound evaluation with a new optical technology, researchers have found a way to more accurately identify low-risk lesions, potentially sparing thousands of women from unnecessary invasive surgery.
Understanding the Technology: Diffuse Optical Tomography
The breakthrough comes from a team led by Quing Zhu, the Edwin H. Murty Professor of Engineering at Washington University in St. Louis, and Debbie Bennett, MD, chief of breast imaging for WashU Medicine Mallinckrodt Institute of Radiology. They developed a technique called ultrasound-guided diffuse optical tomography.
Unlike traditional imaging, this method uses near-infrared light to create 3D pictures of breast tissue. The technology focuses on functional differences between healthy and malignant tissues, specifically looking at:
- Blood vascular contrast: Analyzing the structure and density of blood vessels.
- Oxygen levels: Measuring blood oxygen saturation to identify markers of cancer.
When these functional maps are combined with standard ultrasound imaging, radiologists can make more confident diagnoses. For example, high total hemoglobin concentration (HbT) levels combined with low blood oxygen saturation often raise suspicion for malignancy, helping doctors decide more accurately who truly needs a biopsy.
The Clinical Trial and Results
To test the effectiveness of this tool, the research team conducted a double-blind clinical trial involving 226 patients. The results, published online in Breast Cancer Research on December 31, 2025, demonstrate a significant improvement in diagnostic accuracy.
The study found that the technology can reduce unnecessary breast biopsy rates by nearly 25%. Crucially, the tool maintained a low false negative rate of below 2%. This performance falls well within the standard of care biopsy decision risk guidelines set by the American College of Radiology.
Why This Matters for Patient Care
The impact of a 25% reduction in benign biopsies is substantial given the scale of breast screenings in the U.S. With more than 1 million breast biopsies performed annually, this technology could lead to:
- Reduced Patient Anxiety: Fewer women would have to undergo invasive procedures for lesions that are ultimately harmless.
- Lower Healthcare Costs: Reducing the volume of unnecessary biopsies decreases the financial burden on the healthcare system.
- More Efficient Triage: Doctors can prioritize high-risk patients more effectively, ensuring those with cancer receive treatment faster.
This research was supported by a grant of nearly $2 million from the National Cancer Institute of the National Institutes of Health (NIH), highlighting the importance of developing noninvasive alternatives to traditional biopsy triggers.
Key Takeaways
- The Problem: 75% to 80% of U.S. Breast biopsies are benign.
- The Solution: Ultrasound-guided diffuse optical tomography using near-infrared light.
- The Result: A nearly 25% reduction in unnecessary biopsies with a false negative rate under 2%.
- The Benefit: Lower healthcare costs and decreased patient stress.
Frequently Asked Questions
Does this replace the biopsy entirely?
No. A biopsy remains the only way to definitively determine if a lump is cancerous. This imaging tool acts as a triage mechanism to assist doctors decide which lesions are low-risk enough to avoid a biopsy and which ones absolutely require one.
Is this technology currently available in all hospitals?
The technology was validated through a clinical trial led by Washington University in St. Louis and Barnes-Jewish Hospital. While the results are promising and published, widespread clinical adoption typically follows these successful trial phases.
What makes this different from a standard ultrasound?
Standard ultrasounds look at the structure of the tissue. Diffuse optical tomography looks at the function of the tissue, specifically how blood and oxygen are moving, which provides an extra layer of evidence to distinguish between benign and malignant masses.
As noninvasive imaging continues to evolve, the goal is to move toward a future where the “biopsy burden” is minimized, ensuring that invasive procedures are reserved only for those who truly need them.
Related reading